关键词: 分枝杆菌,结核, 抗药性, 再治疗

Abstract:

Objective To analyze the drug resistance of Mycobacterium tuberculosis in the patients who had tuberculosis and received repeated treatment with the treatment interval ≥2 years. Methods A retrospective analysis method was used. The data and information of 44 tuberculosis patients, who were repeatedly treated with two years or more treatment interval in the Infectious Diseases Hospital Affiliated to Soochow University from January 2013 to December 2020 were collected. Their drug resistance situation (including rifampicin, isoniazid, amikacin, ethambutol, moxifloxacin, levofloxacin, p-aminosalicylic acid, prothionamide and streptomycin) at baseline and after received repeated treatment were compared and analyzed. Results The baseline drug resistance rates of rifampicin, isoniazid, amikacin, levofloxacin, p-aminosalicylic acid and streptomycin in those 44 tuberculosis patients were 20.5% (9/44), 31.8% (14/44), 22.7% (10/44), 7.9% (3/38), 5.4% (2/37) and 3.1% (1/32) respectively and there were no drug resistance strains to ethambutol, moxifloxacin and prothionamide; After received repeated treatment, the drug resistance rates of rifampicin, isoniazid, amikacin, ethambutol, moxifloxacin, levofloxacin, p-aminosalicylic acid, prothionamide and streptomycin in those patients were 38.6% (17/44), 43.2% (19/44), 20.5% (9/44), 13.6% (6/44), 12.8% (5/39), 15.8% (6/38), 8.1% (3/37), 18.4% (7/38) and 6.2% (2/32) respectively. The types of drug resistance increased in 17 patients. Five patients developed pre-extensive drug resistance. Conclusion The increased drug resistance rate of Mycobacterium tuberculosis and the increased types of drug resistance are related to the history of tuberculosis treatment. During the anti-tuberculosis treatment, the drug resistance should be closely paid attention and monitored, and the anti-tuberculosis drugs should be rationally used.

Key words: Mycobacterium tuberculosis, Drug resistance, Retreatment